NewAmsterdam Pharma Company N.V.NASDAQ: NAMS

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

· Issued by NewAmsterdam Pharma Company N.V.

-- Achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p

NewAmsterdam Pharma Company N.V. on 6ix

In the deck

Story so far

Earlier from NewAmsterdam Pharma

Later from NewAmsterdam Pharma

All NewAmsterdam Pharma news releases